Mitsubishi Tanabe taps Synageva for orphan drug R&D
This article was originally published in Scrip
The US orphan drug firm Synageva BioPharma is to carry out research into a novel therapeutic molecule for an undisclosed but "devastating" orphan disease in a new collaboration with Mitsubishi Tanabe Pharma (MTP).
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.